The economic burden of advanced gastric cancer in Taiwan
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Jihyung | - |
dc.contributor.author | Tsai, Yiling | - |
dc.contributor.author | Novick, Diego | - |
dc.contributor.author | Hsiao, Frank Chi-Huang | - |
dc.contributor.author | Cheng, Rebecca | - |
dc.contributor.author | Chen, Jen-Shi | - |
dc.date.available | 2020-02-27T17:42:03Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2017-09-16 | - |
dc.identifier.issn | 1472-6963 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/5705 | - |
dc.description.abstract | Background: Gastric cancer is one of the leading causes of cancer-related deaths in both sexes worldwide, especially in Eastern Asia. This study aimed to estimate the economic burden of advanced gastric cancer (AGC) in Taiwan. Methods: The costs of AGC in 2013 were estimated using resource use data from a chart review study (n = 122 with AGC) and national statistics. Annual per-patient costs, where patients' follow-up periods were adjusted for, were estimated with 82 patients who had complete resource use data. The costs were composed of direct medical costs, direct non-medical costs (healthcare travel and caregiver costs), morbidity costs, and mortality costs. Relevant unit costs were retrieved mainly from literature and national statistics, and applied to the resource use data. A broad definition of morbidity and mortality costs was employed to value the productivity loss in patients with unpaid employment, economically inactive and unemployed as well as the life years after the age of retirement. Their narrow definitions were also used in sensitivity analyses, using age-and/or sex-specific employment rates. Forgone future earnings/productivity loss were discounted at 3%. Annual per-patient costs were projected to estimate the total costs of AGC at the national level with an estimated number of patients with AGC (N = 2611) in Taiwan in 2013. Results: The mean age of the 82 patients was 59.3 (SD: 11.9) years, and 67.1% were male. Per-patient costs were US$ 26,431 for direct medical costs, US$ 4669 for direct non-medical costs, US$ 5758 for morbidity costs, and US$ 145,990 for mortality costs (per death). These per-patient costs were projected to incur total AGC costs of US$ 423 million at the national-level. Mortality costs accounted for 77.3% of the total costs, followed by direct medical costs (16.3%), morbidity costs (3.6%), and direct non-medical costs (2.9%). Conclusion: AGC was found to exert a significant economic burden in Taiwan, incurring US$ 423 million in 2013. This represents about 0.08% of the Taiwanese economy. Mortality costs appeared to be the single greatest contributor to the burden, followed by direct medical costs. Early detection and providing effective treatments will help to reduce its burden on patients, caregivers and society as a whole. A poster of this study was presented at the 2016 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco, CA, USA. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.relation.isPartOf | BMC HEALTH SERVICES RESEARCH | - |
dc.subject | RANDOMIZED PHASE-III | - |
dc.subject | SUPPORTIVE CARE | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | SURVIVAL | - |
dc.subject | TRIAL | - |
dc.title | The economic burden of advanced gastric cancer in Taiwan | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000410784000003 | - |
dc.identifier.doi | 10.1186/s12913-017-2609-1 | - |
dc.identifier.bibliographicCitation | BMC HEALTH SERVICES RESEARCH, v.17 | - |
dc.identifier.scopusid | 2-s2.0-85029544890 | - |
dc.citation.title | BMC HEALTH SERVICES RESEARCH | - |
dc.citation.volume | 17 | - |
dc.contributor.affiliatedAuthor | Hong, Jihyung | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | Burden of illness | - |
dc.subject.keywordAuthor | Cost | - |
dc.subject.keywordAuthor | Taiwan | - |
dc.subject.keywordPlus | RANDOMIZED PHASE-III | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | TRIAL | - |
dc.relation.journalResearchArea | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Health Care Sciences & Services | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.